Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
Antonino TuttolomondoAnna CirrincioneAlessandra CasuccioAlessandro Del CuoreMario DaidoneTiziana Di ChiaraDomenico Di RaimondoVittoriano Della CorteCarlo MaidaIrene SimonettaStefania ScaglioneAntonio PintoPublished in: Cardiovascular diabetology (2021)
Our randomized trial showed that subjects with type 2 diabetes treated with conventional therapy plus 1.5 mg/day of subcutaneous dulaglutide compared with subjects treated with conventional therapy alone showed favourable metabolic effects associated with positive effects on vascular health markers such as arterial stiffness and endothelial function markers. These findings are consistent with previous study findings indicating the strict relationship between cardiovascular risk factors such as systolic blood pressure, total serum cholesterol and LDL levels and cardiovascular events and vascular health surrogate markers.
Keyphrases
- blood pressure
- cardiovascular events
- cardiovascular risk factors
- public health
- healthcare
- mental health
- cardiovascular disease
- health information
- coronary artery disease
- heart failure
- hypertensive patients
- health promotion
- stem cells
- heart rate
- low density lipoprotein
- skeletal muscle
- climate change
- insulin resistance
- newly diagnosed
- atrial fibrillation
- replacement therapy